Clinical Research Directory
Browse clinical research sites, groups, and studies.
Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)
Sponsor: Nanjing Medical University
Summary
Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with cardiovascular diseases. Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with sivelestat may be beneficial. This study was designed to test the hypothesis that the administration of sivelestat during the acute phase of cardiovascular diseases will result in a reduced incidence of SIRS and MODS.
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
500
Start Date
2024-07-01
Completion Date
2025-12-31
Last Updated
2024-11-22
Healthy Volunteers
No
Interventions
Sivelestat
The total 24-hour dose of Sivelestat sodium (4.8mg/kg) was dissolved with 50 ml normal saline. The drug flow rate was set at 2ml/h with an intravenous microinfusion pump, and the constant speed infusion was completed in 24h.
Blank control
Patients only received standard treatment and care.
Locations (2)
Beijing Anzhen Hospital
Beijing, China
The First Affiliated Hospital of Nanjing Medical University and Jiang ye-fan
Nanjing, China